Vinflunine in the treatment of bladder cancer

Therapeutics and Clinical Risk Management

Volumn 4, Issue 6, 2008, Pages 1243-1253

  Bachner, Mark ^a   De Santis, Maria ^a  

^a KAISER FRANZ JOSEF HOSPITAL   (Austria)

Author keywords

Bladder cancer; Chemotherapy; Second line chemotherapy; Transitional cell carcinoma (TCC) of the bladder; Vinflunine

Indexed keywords

CAMPTOTHECIN; CISPLATIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; JAYLOR; METHOTREXATE; MITOMYCIN C; NAVELBINE; PACLITAXEL; TUBULIN; UNCLASSIFIED DRUG; VFL; VINBLASTINE; VINFLUNINE;

ABDOMINAL PAIN; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BLADDER CANCER; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; CREATININE BLOOD LEVEL; CYTOTOXICITY; DIARRHEA; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; INFECTION; INJECTION SITE REACTION; LEUKOPENIA; MAXIMUM TOLERATED DOSE; MICROTUBULE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA AND VOMITING; NEUTROPENIA; OPTIMAL DRUG DOSE; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PROGRESSION FREE SURVIVAL; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; STOMATITIS; THORAX PAIN; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA;

EID: 61549102521     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/tcrm.s3384     Document Type: Review

References (104)

1. Advanced Bladder Cancer Meta-analysis Collaboration. 2003. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet, 361:1927-34.
2. Advanced Bladder Cancer Meta-analysis Collaboration. 2005a. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol, 48:189-99; discussion 199-201.
3. Advanced Bladder Cancer Meta-analysis Collaboration. 2005b. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol, 48:202-5; discussion 205-6.
4. Albers P, Siener R, Hartlein M, et al. 2002. Gemcitabine monotherapy as second-line treatment in cisplatin-refractory transitional cell carcinoma - prognostic factors for response and improvement of quality of life. Onkologie, 25:47-52.
5. Albers P, Siener R, Park S, et al. 2008. Randomized phase III trial of 2nd line gemcitabine/paclitaxel chemotherapy in patients with advanced bladder cancer: Temporary versus maintenance treatment (German Association of Urologic Oncology (AUO) Trial AB 20/99). J Clin Oncol, 26(20 Suppl).
6. Baguley BC, Holdaway KM, Thomsen LL, et al. 1991. Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. Eur J Cancer, 27:482-7.
7. Bajorin DF, Dodd PM, Mazumdar M, et al. 1999. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol, 17:3173-81.
8. Barret JM, Etievant C, Hill BT. 2000. In vitro synergistic effects of vinflunine, a novel fluorinated vinca alkaloid, in combination with other anticancer drugs. Cancer Chemother Pharmacol, 45:471-6.
9. Bassi P, Ferrante GD, Piazza N, et al. 1999. Prognostic factors of outcome after radical cystectomy for bladder cancer: a retrospective study of a homogeneous patient cohort. J Urol, 161:1494-7.
10. Bellmunt J, Cos J, Cleries R, et al. 2002. Feasibility trial of methotrexate-paclitaxel as a second line therapy in advanced urothelial cancer. Cancer Invest, 20:673-85.
11. Bellmunt J, Delgado FM, George C. 2008. Clinical Activity of Vinflunine in Transitional Cell Carcinoma of the Urothelium and Other Solid Tumors. Semin Oncol, 35: S34-S43.
12. Bellmunt Molins J, von der Maase H, Theodore C, et al. 2008. Randomised phase III trial of vinflunine (V) plus best supportive care (B) vs B alone as 2nd line therapy after a platinum-containing regimen in advanced transitional cell carcinoma of the urothelium (TCCU). J Clin Oncol, 26(20 Suppl).
13. Bennouna J, Fumoleau P, Armand JP, et al. 2003. Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours. Ann Oncol, 14:630-7.
14. Bennouna J, Vermorken JB, Senellart H, et al. 2008. Phase I dose-escalation study of oral vinflunine given twice a day for 2 consecutive days every week in patients with solid tumours. J Clin Oncol, 26(20 Suppl).
15. Bonfil RD, Russo DM, Binda MM, et al. 2002. Higher antitumor activity of vinflunine than vinorelbine against an orthotopic murine model of transitional cell carcinoma of the bladder. Urol Oncol, 7:159-66.
16. Braguer D, Barret JM, McDaid H, et al. 2008. Antitumor Activity of Vinflunine: Effector Pathways and Potential for Synergies. Semin Oncol, 35:S13-S21.
17. Bunn PA Jr, Kelly K. 1998. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res, 4:1087-100.
18. Chen AC, Hovey E, Shelton G, et al. 2004. Phase I/II study of docetaxel (D), gemcitabine (G), Carboplatin (C) in poor prognosis and previously treated patients (pts) with urothelial carcinoma (UTC). J Clin Oncol, 22; 2004. ASCO Annual Meeting Proceedings (Post-Meeting Edition) 14S (July 15 Supplement): 4580.
19. Culine S, Theodore C, De Santis M, et al. 2006. A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer, 94:1395-401.
20. Culine S. 2002. The present and future of combination chemotherapy in bladder cancer. Semin Oncol, 29: 32-9.
21. Dalbagni G, Genega E, Hashibe M, et al. 2001. Cystectomy for bladder cancer: a contemporary series. J Urol, 165:1111-6.
22. De Mulder PH, Theodore C, Sella A, et al. 2000. Phase II EORTC trial with 5-fluorouracil, cisplatin and interferon-alpha as second-line treatment of advanced transitional cell cancer of the urothelial tract. Ann Oncol, 11:1391-4.
23. Delord JP, Stupp R, Pinel MC, et al. 2001. Phase I Study of vinflunine given as a 10 minute intravenous (iv) Infusion on a weekly schedule in patients (pts) with advanced solid tumours. Proc Am Soc Clin Oncol, 20:2001.
24. Dodd PM, McCaffrey JA, Mazumdar M, et al. 2000. Phase II trial of pyrazoloacridine as second-line therapy for patients with unresectable or metastatic transitional cell carcinoma. Invest New Drugs, 18:247-51.
25. Dreicer R, Li S, Manola J, et al. 2007. Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): a trial of the Eastern Cooperative Oncology Group. Cancer, 110:759-63.
26. Etievant C, Barret JM, Kruczynski A, et al. 1998. Vinflunine (20′,20′-difluoro-3′,4′-dihydrovinorelbine), a novel Vinca alkaloid, which participates in P-glycoprotein (Pgp)-mediated multidrug resistance in vivo and in vitro. Invest New Drugs, 16:3-17.
27. Etievant C, Kruczynski A, Barret JM, et al. 2001. Markedly diminished drug resistance-inducing properties of vinflunine (20′,20′-difluoro-3′, 4′-dihydrovinorelbine) relative to vinorelbine, identified in murine and human tumour cells in vivo and in vitro. Cancer Chemother Pharmacol, 48:62-70.
28. Fabre C, Czaplicki J, Wright M, et al. 2002, Differential binding to the alpha/beta-tubulin dimer of vinorelbine and vinflunine revealed by nuclear magnetic resonance analyses. Biochem Pharmacol, 64:733-40.
29. Fahy J, Duflos A, Ribet JP, et al. 1997. Vinca Alkaloids in Superacidic Media: A Method for Creating a New Family of Antitumor Derivatives. J Am Chem Soc, 119:8576-7.
30. Fahy J, Hellier P, Breillout F, et al. 2008. Vinflunine: discovery and synthesis of a novel microtabule inhibitor. Semin Oncol, 35:S3-S5.
31. Fechner G, Siener R, Reimann M, et al. 2006. Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99). Int J Clin Pract, 60:27-31.
32. Focan CN, Van Heugen J-C, Kreutz F, et al. 2002. Vinflunine metabolism and disposition in cancer patients. Proc Am Soc Clin Oncol, 21.
33. Galsky MD, Mironov S, Iasonos A, et al. 2007. Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. Invest New Drugs, 25:265-70.
34. Gebbia V, Testa A, Borsellino N, et al. 1999. Single agent 2′, 2′-difluorodeoxycytidine in the treatment of metastatic urothelial carcinoma: a phase II study. Clin Ter, 150:11-5.
35. Ghoneim MA, el-Mekresh MM, el-Baz MA, et al. 1997. Radical cystectomy for carcinoma of the bladder: critical evaluation of the results in 1,026 cases. J Urol, 158:393-9.
36. Gout PW, Noble RL, Bruchovsky N, et al. 1984. Vinblastine and vincristine-growth-inhibitory effects correlate with their retention by cultured Nb 2 node lymphoma cells. Int J Cancer, 34:245-8.
37. Gregory RK and Smith IE. 2000. Vinorelbine - a clinical review. Br J Cancer, 82:1907-13.
38. Hill BT, Fiebig HH, Waud WR, et al. 1999. Superior in vivo experimental antitumour activity of vinflunine, relative to vinorelbine, in a panel of human tumour xenografts. Eur J Cancer, 35:512-20.
39. Hill BT. 2001. Vinflunine, a second generation novel vinca alkaloid with a distinctive pharmacological profile, now in clinical development and prospects for future mitotic blockers. Curr Pharm Des, 7:1199-212.
40. Hill SA, Lonergan SJ, Denekamp J, et al. 1993. Vinca alkaloids: anti-vascular effects in a murine tumour. Eur J Cancer, 29A:1320-4.
41. Holwell SE, Hill BT, Bibby MC. 2001. Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model. Br J Cancer, 84:290-5.
42. Hortobagyi GN. 2000. Developments in chemotherapy of breast cancer. Cancer, 88:3073-9.
43. Jean-Decoster C, Brichese L, Barret JM, et al. 1999. Vinflunine, a new vinca alkaloid: cytotoxicity, cellular accumulation and action on the interphasic and mitotic microtubule cytoskeleton of PtK2 cells. Anti-cancer Drugs, 10: 37-43.
44. Johnson P, Geldart T, Fumoleau P, et al. 2006. Phase I study of vinflunine administered as a 10-minute infusion on days 1 and 8 every 3 weeks. Invest New Drugs, 24:223-31.
45. Johnson P, O'Donnell A, Pinel MC, et al. 2001. Phase I Study of Vinflunine Given as a 10 Minute Infusion on Days 1 and 8 Every 3 Weeks in Patients (Pts) with Solid Malignancies. Proc Am Soc Clin Oncol, 20.
46. Johnson SA, Harper P, Hortobagyi GN, et al. 1996. Vinorelbine: an overview. Cancer Treat Rev, 22:127-42.
47. Joly F, Tchen N, Chevreau C, et al. 2004. Clinical benefit of second line weekly paclitaxel in advanced urothelial carcinoma (AUC): A GETUG phase II study. J Clin Oncol, 22:2004. ASCO Annual Meeting Proceedings (Post-Meeting Edition) 14S (July 15 Supplement):4619.
48. Jordan MA, Band Horwitz S, Lobert S, et al. 2008. Exploring the Mechanisms of Action of the Novel Microtubule Inhibitor Vinflunine. Semin Oncol, 35:S6-S12.
49. Jordan MA, Himes RH, Wilson L. 1985. Comparison of the effects of vinblastine, vincristine, vindesine, and vinepidine on microtubule dynamics and cell proliferation in vitro. Cancer Res, 45: 2741-7.
50. Jordan MA, Thrower D, Wilson L. 1991. Mechanism of inhibition of cell proliferation by Vinca alkaloids. Cancer Res, 51:2212-22.
51. Kaufman D, Stadler W, Carducci M, et al. 2000. Gemcitabine (G) and Paclitaxel (P) Every Two Weeks (GP2W): A Multicenter Phase II Trial in Locally Advanced or Metastatic Urothelial Cancer (UC). Proc Am Soc Clin Oncol, 19.
52. Kavallaris M, Annereau J-P, Barret J-M. 2008. Potential Mechanisms of Resistance to Microtubule Inhibitors. Semin Oncol, 35:S22-S27.
53. Khorsand M, Lange J, Feun L, et al. 1997. Phase II trial of oral piritrexim in advanced, previously treated transitional cell cancer of bladder. Invest New Drugs, 15:157-63.
54. Krege S, Rembrink V, Borgermann C, et al. 2001. Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a phase 2 study. J Urol, 165:67-71.
55. Kruczynski A, Barret JM, Etievant C, et al. 1998a. Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated vinca alkaloid. Biochem Pharmacol, 55:635-48.
56. Kruczynski A, Colpaert F, Tarayre JP, et al. 1998b. Preclinical in vivo antitumor activity of vinflunine, a novel fluorinated vinca alkaloid. Cancer Chemother Pharmacol, 41:437-47.
57. Kruczynski A, Etievant C, Perrin D, et al. 2002. Characterization of cell death induced by vinflunine, the most recent Vinca alkaloid in clinical development. Br J Cancer, 86:143-50.
58. Le Chevalier T, Brisgand D, Douillard JY, et al. 1994. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol, 12:360-7.
59. Lemarie E, Bennouna J, Grossi F, et al. 2005. Vinflunine (VFL) in combination with gemcitabine (GEM) for treatment of advanced non-small cell lung cancer (NSCLC) in chemonaive patients (pts): Preliminary results of the phase I and pharmacokinetic study. J Clin Oncol, 23; 2005. ASCO Annual Meeting Proceedings (Post-Meeting Edition) 16S (July 15 Suppl):7266.
60. Lin CC, Hsu CH, Huang CY, et al. 2007. Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: a phase II study. Anticancer Drugs, 18:487-91.
61. Lobert S and Puozzo C. 2008. Pharmacokinetics, metabolites, and preclinical safety of vinflunine. Semin Oncol, 35:S28-S33.
62. Lobert S, Ingram JW, Hill BT, et al. 1998. A comparison of thermodynamic parameters for vinorelbine- and vinflunine-induced tubulin self-association by sedimentation velocity. Mol Pharmacol, 53:908-15.
63. Loehrer PJ Sr, Einhorn LH, Elson PJ, et al. 1992. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol, 10: 1066-73.
64. Logothetis CJ, Dieringer P, Ellerhorst J, et al. 1992. A 61% response rate with 5-fluorouracil, interferon-a 2b and cisplatin in metastatic chemotherapy refractory transitional cell carcinoma. Proc Am Assoc Cancer Res, 33:221.
65. Lorusso V, Pollera CF, Antimi M, et al. 1998. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur J Cancer, 34:1208-12.
66. McCaffrey JA, Hilton S, Mazumdar M, et al. 1997. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol, 15:1853-7.
67. Meluch AA, Greco FA, Burris HA 3rd, et al. 2001. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network. J Clin Oncol, 19:3018-24.
68. Moore M, Winquist E, Vokes E, et al. 2003. Phase II study of oxaliplatin in patients with inoperable, locally advanced or metastatic transitional cell carcinoma of the urothelial tract (TCC) who have received prior chemotherapy. Proc Am Soc Clin Oncol, 22.
69. Ngan VK, Bellman K, Hill BT, et al. 2001. Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative vinflunine. Mol Pharmacol, 60:225-32.
70. Ngan VK, Bellman K, Panda D, et al. 2000. Novel actions of the antitumor drugs vinflunine and vinorelbine on microtubules. Cancer Res, 60:5045-51.
71. Pagliaro LC, Millikan RE, Tu SM, et al. 2002. Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma. J Clin Oncol, 20:2965-70.
72. Papamichael D, Gallagher CJ, Oliver RT, et al. 1997. Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter. Br J Cancer, 75:606-7.
73. Paridaens R, Wildiers H, Dalenc F, et al. 2007. Vinflunine in combination with trastuzumab for treatment of HER2-positive metastatic breast cancer. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 1058.
74. Parkin DM, Bray F, Ferlay J, et al. 2005. Global cancer statistics, 2002. CA Cancer J Clin, 55: 74-108.
75. Paule B, Saliba F, Gil-Delgado M, et al. 2007. Phase I and pharmacokinetic (PK) dose-adjusted study of IV vinflunine (VFL) in cancer patients with liver dysfunction (LD): Pharmacokinetic results. J Clin Oncol, 25; 2007. ASCO Annual Meeting Proceedings 25(18S) (June 20 Suppl): 2523.
76. Pourroy B, Carre M, Honore S, et al. 2004. Low concentrations of vinflunine induce apoptosis in human SK-N-SH neuroblastoma cells through a postmitotic G1 arrest and a mitochondrial pathway. Mol Pharmacol, 66:580-91.
77. Pronzato P, Vigani A, Pensa F, et al. 1997. Second line chemotherapy with ifosfamide as outpatient treatment for advanced bladder cancer. Am J Clin Oncol, 20: 519-21.
78. Puozzo C, Vermorken JB, Bauer J, et al. 2001. A Phase I Pharmacokinetic Study of Vinflunine Given on a Weekly Schedule. Proc Am Soc Clin Oncol, 20.
79. Ramlau R, Souquet P-J, Sun X, et al. 2004. Results of a phase I/II and pharmacokinetic study of vinflunine (VFL) in combination with cisplatin (CDDP) for primary treatment of advanced non-small cell lung cancer (NSCLC). J Clin Oncol, 22:2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) (14S) (July 15 Suppl): 7110.
80. Rosenberg JE, Carroll PR, Small EJ. 2005. Update on chemotherapy for advanced bladder cancer. J Urol, 174:14-20.
81. Roth BJ, Manola J, Dreicer R, et al. 2002. Piritrexim in advanced, refractory carcinoma of the urothelium (E3896): a phase II trial of the Eastern Cooperative Oncology Group. Invest New Drugs, 20:425-9.
82. Saliba F, Paule B, Adam R, et al. 2007. Vinflunine in patients with advanced unresectable hepatocellular carcinoma and liver impairment. J Clin Oncol, 25; 2007 ASCO Annual Meeting Proceedings (18S) (June 20 Suppl):15023.
83. Shah U, Sanoff HK, O'Neil BH, et al. 2008. A phase I trial of pemetrexed and vinflunine (VFL). J Clin Oncol, 26(May 20 Suppl).
84. Singer WD and Himes RH. 1992. Cellular uptake and tubulin binding properties of four Vinca alkaloids. Biochem Pharmacol, 43:545-51.
85. Sridhar SS, Stadler W, Le L, et al. 2005. Phase 2 study of Bortezomib in Advanced or Metastatic Urothelial Cancer. A trial of the Princess Margaret Hospital [PMH] Phase II Consortium. J Clin Oncol, 23; ASCO Annual Meeting Proceedings (16S, Part I of II)(June 1 Suppl): 4677.
86. Stein JP, Lieskovsky G, Cote R, et al. 2001. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol, 19:666-75.
87. Stein JP. 2006. Improving outcomes with radical cystectomy for high-grade invasive bladder cancer. World J Urol, 24:509-16.
88. Sternberg CN and Vogelzang NJ. 2003. Gemcitabine, paclitaxel, pemetrexed and other newer agents in urothelial and kidney cancers. Crit Rev Oncol Hematol, 46(Suppl):S105-15.
89. Sternberg CN, Calabro F, Pizzocaro G, et al. 200). Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer, 92:2993-8.
90. Sternberg CN, Yagoda A, Scher HI, et al. 1988. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol, 139:461-9.
91. Sweeney CJ, Roth BJ, Kabbinavar FF, et al. 2006. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol, 24:3451-7.
92. Sweeney CJ, Williams SD, Finch DE, et al. 1999. A Phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium. Cancer, 86:514-8.
93. Tourani J, Pinel M, Planchard D, et al. 2005. Phase I and pharmacokinetic study of Vinflunine (VFL) in combination with carboplatin (CBDCA) for treatment of advanced non-small cell lung cancer (NSCLC) in chemonaive patients (pts): Final results. J Clin Oncol, 23; ASCO Annual Meeting Proceedings (16S, Part I of II1) (June 1 Suppl): 7271.
94. Tu SM, Hossan E, Amato R, et al. 1995. Paclitaxel, cisplatin and methotrexate combination chemotherapy is active in the treatment of refractory urothelial malignancies. J Urol, 154:1719-22.
95. Vaishampayan UN, Faulkner JR, Small EJ, et al. 2005. Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma: a Southwest Oncology Group study. Cancer, 104:1627-32.
96. Vaughn DJ, Broome CM, Hussain M, et al. 2002. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol, 20:937-40.
97. Vaughn DJ, Srinivas S, Petrylak DP, et al. 2008. Vinflunine (VFL) in patients with platinum-refractory transitional cell carcinoma of the urothelium (TCCU): results of a large phase 2 study. 2008. ASCO Genitourinary Cancers Symposium.
98. Vermorken JB, Stupp R, Nguyen L, et al. 2003. Phase I Study of IV vinflunine given on a weekly schedule in previously untreated patients (pts) with advanced solid tumors. Proc Am Soc Clin Oncol, 22.
99. von der Maase H, Hansen SW, Roberts JT, et al. 2000. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol, 18:3068-77.
100. Winquist E, Kirchner TS, Segal R, et al. 2004. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J Urol, 171:561-9.
101. Witte RS, Elson P, Bono B, et al. 1997. Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. J Clin Oncol, 15:589-93.
102. Witte RS, Manola J, Burch PA, et al. 1998. Topotecan in previously treated advanced urothelial carcinoma: an ECOG phase II trial. Invest New Drugs, 16:191-5.
103. Wülfing C, Machiels J, Richel D, et al. 2005. A single arm, multicenter, open-label, ph II study of lapatinib as 2L treatment of pts with locally advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract. J Clin Oncol, 23; ASCO Annual Meeting Proceedings. (16S, Part I of II) (June 1 Suppl):4594.
104. Zorza G, Johnson P, Judson I, et al. 2001. A Phase I Pharmacokinetic Study of Vinflunine Given on Days 1 and 8 Every 3 Weeks. Proc Am Soc Clin Oncol, 20.